Credit Suisse reported on Thursday that they have lowered their rating on biopharmaceutical company, Pfizer Inc.(PFE).
The firm has downgraded PFE from “Outperform” to “Neutral,” and has given the company a $29 price target. This price target suggests a 6% increase from the stock’s current price of $27.20.
Pfizer shares were down 19 cents, or -0.70% during Thursday morning trading. The stock has increased 29% in the past year.
The Bottom Line
Shares of Pfizer Inc.(PFE) have a 3.53% yield, based on Thursday morning’s price of $27.20.
Pfizer Inc.(PFE) is a “Recommended” dividend stock at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
FREE Dividend Stock Newsletter
Get the Dividend.com email newsletter to receive:
- A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
- Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
- Tons of great market analysis and recommendations